ALLMedicine™ Osteogenesis Imperfecta Center

Jan 27th, 2023 - Participants in Phase 2 will be randomized 1:1 to receive low dose or high dose setrusumab. Participants will continue receiving their assigned dose until the selected dosing strategy is determined for the remainder of the study. Phase 2 participa...

Jan 26th, 2023 - Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functio...

Jan 26th, 2023 - We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 30 years. A consistent objective throughout this study is to obtain a comprehensive assessment of the natural history and ...

Jan 21st, 2023 - Osteogenesis Imperfecta (OI) is a genetic disorder characterized by increased bone fragility largely caused by defects in structure, synthesis, or post-translational processing of type I collagen. The effectiveness of medications used for fracture...

Jan 20th, 2023 - Osteogenesis imperfecta (OI) is a group of rare skeletal dysplasia. Long bone deformity and scoliosis are often associated with progressively deforming types of OI. FKBP65 (encoded by FKBP10, OMIM *607063) plays a crucial role in the processing of...

Jan 15th, 2023 - Pulmonary involvement in Osteogenesis Imperfecta (OI) can be severe but may be overlooked in milder cases. The Care4BrittleBones Foundation initiated this project to develop a set of global outcome measures focusing on respiratory-related issues i...

Mar 6th, 2018 - Bisphosphonate therapy is the mainstay of pharmacological intervention in young people with skeletal fragility. The evidence of its use in a variety of conditions remains limited despite over three decades of clinical experience. On behalf of the ...

Jan 27th, 2023 - Participants in Phase 2 will be randomized 1:1 to receive low dose or high dose setrusumab. Participants will continue receiving their assigned dose until the selected dosing strategy is determined for the remainder of the study. Phase 2 participa...

Jan 26th, 2023 - Osteogenesis imperfecta (OI) is a rare genetic disorder of increased bone fragility and low bone mass. It is conceivable that children and adolescents with OI are less active than healthy peers because of frequent fractures, immobilization,functio...

Jan 26th, 2023 - We propose a longitudinal study of the natural history of types III and IV osteogenesis imperfecta for children age birth to 30 years. A consistent objective throughout this study is to obtain a comprehensive assessment of the natural history and ...

Jan 11th, 2023 - The duration of the study for all participants will be approximately 29 weeks: Up to 5 weeks from initiation of screening to dose administration Treatment on Day 1 Follow-up and observation of safety and PD for 24 weeks Final study visit at Week 24

Jan 9th, 2023 - This protocol seeks to formalize the application of accepted diagnostic and therapeutic measures in the study of individuals with known or suspected bone-related connective tissue disorders, including Osteogenesis Imperfecta and melorheostosis. It...

Mar 29th, 2022 - Everyone can benefit from good oral hygiene, but people with cancer need to pay particular attention to their dental health because of side effects associated with certain treatments. Osteonecrosis of the jaw (ONJ) involves dead bone in the jaw ...

Feb 28th, 2022 - NEW YORK (Reuters Health) - In adults with osteogenesis imperfecta (OI), a single administration of fresolimumab, a pan-anti-TGF-beta neutralizing antibody, improved bone mass and turnover in a phase 1 study. Currently, there is no specific therap...

Dec 5th, 2020 - University of Pennsylvania's Abramson Cancer Center Established in 1973 as the University of Pennsylvania’s Cancer Center and subsequently renamed in 2002, the Abramson Cancer Center is a world leader in research, patient care, and education. ...

Jul 14th, 2020 - NEW YORK (Reuters Health) - Fetal gene and stem-cell therapies are emerging as treatment options for select conditions, according to a new review. "Fetal cellular and gene therapies are feasible and primed to become viable treatments for a number ...

Aug 8th, 2018 - The OIF will host its biennial national conference in Baltimore July 13-15, 2018. The program will feature sessions on medical care and practical living, forums with leading experts in osteogenesis imperfect care and research, and other opportunit.